Retho-Cialis

RETHO-CIALIS BY BELIGAS PHARMACEUTICALS

Tablets

DRUG COMPOSITION

1 tablet contains:
- active substance: tadalafil citrate 25 mg;
- auxiliary substances:

DRUG DESCRIPTION

PHARMACEUTICAL FORM

Tablets.

PHARMACEUTICAL GROUP AND ATC CODE

PDE5 Inhibitor.

PHARMACOLOGICAL PROPERTIES

PROFILE

Half life: 17.5 Hours
Routes of administration: by mouth
Dosage forms: (Men): 10-20 mg/day; (Women): -
Acne: no
Water retention: no
High blood pressure: perhaps
Hepatotoxicity: no
Aromatase: no
Decreased HPTA function (own testosterone production): none
Anabolic activity: Not a steroid
Androgenic activity: Not a steroid
Detection time:

THERAPEUTICAL INDICATIONS

DOSES AND METHOD OF ADMINISTRATION

SIDE EFFECTS

CONTRAINDICATIONS

OVERDOSE

INTERACTIONS WITH OTHER DRUGS

PRESENTATION, PACKAGING

25 mg tablets.
50 tablets in sachets.

STORAGE

Store in a dry place and away from light at 15-25 ° C. Keep out of the reach and sight of children.

LEGAL STATUS

It is issued with prescription.

DATE OF LAST TEXT CHECKS

March 2020

NAME AND ADDRESS OF THE MANUFACTURER

Beligas Pharmaceuticals
Belgium